Veru Inc. (VERU)

5,76 -0,15 (-2,54%) Börsenschluss: 04:00PM EST

Veru Inc.

48 NW 25th Street
Suite 102
Miami, FL 33127
United States
305 509 6897
https://www.verupharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 252

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D.	Chairman, Pres & CEO	1,43M	N/A	1961
Dr. Harry Fisch F.A.C.S., M.D.	Vice Chairman & Chief Corp. Officer	648,12k	N/A	1959
Ms. Michele Greco	CFO & Chief Admin. Officer	659,62k	N/A	1959
Dr. K. Gary Barnette Ph.D.	Chief Scientific Officer	636,7k	N/A	1968
Mr. Samuel Fisch	Exec. Director of Investor Relations & Corp. Communications	N/A	N/A	N/A
Mr. Michael J. Purvis	Exec. VP, Gen. Counsel & Corp. Strategy and Sec.	N/A	N/A	N/A
Mr. Kevin J. Gilbert CPA, J.D.	Exec. VP of Corp. Devel.	N/A	N/A	N/A
Dr. Domingo Rodriguez M.D.	Exec. VP of Global Clinical Operations	N/A	N/A	1962
Dr. Gary Bird Ph.D.	Exec. VP of Quality & Regulatory Affairs	N/A	N/A	N/A
Mr. Joel Batten	Exec. VP & GM of Infectious Disease Franchise	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Corporate Governance

Veru Inc.s ISS Governance QualityScore, Stand 1. Oktober 2022, lautet 6. Die grundlegenden Scores sind Audit: 8, Vorstand: 7, Shareholderrechte: 3, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.